<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04940000</url>
  </required_header>
  <id_info>
    <org_study_id>21VADS03</org_study_id>
    <nct_id>NCT04940000</nct_id>
  </id_info>
  <brief_title>Evaluation of the Interest of a Video-assisted Remote Speech Therapy Consultation in Patients With ORL Cancer (TELE ORTHOPHONIE)</brief_title>
  <official_title>Evaluation of the Interest of a Video-assisted Remote Speech Therapy Consultation in Patients With ORL Cancer (TELE ORTHOPHONIE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interventional, prospective, single-centre study aimed to evaluate the impact of a&#xD;
      video-assisted remote speech therapy consultation in relation to the complexity and&#xD;
      specificity of the care of patients with ORL cancer. Three indications will be studied:&#xD;
      phonation problems, swallowing problems and other problems.&#xD;
&#xD;
      The study will be conducted on a population of patients with T3, T4 ORL cancer requiring&#xD;
      speech therapy.&#xD;
&#xD;
      Each patient included will have a video-assisted speech therapy consultation with a private&#xD;
      speech therapist and an expert speech therapist. At the end of this video consultation, the&#xD;
      patient and the private speech therapist will be asked to complete a satisfaction&#xD;
      questionnaire.&#xD;
&#xD;
      At the follow-up visit following the video-assisted consultation, the patient will have&#xD;
      completed participation in the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of patients for whom tele-therapy will be considered successful.</measure>
    <time_frame>12 months for each patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of patients with full or partial resolution of speech-language pathology at the end of the telecare consultation.</measure>
    <time_frame>12 months for each patient</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>ORL Cancer</condition>
  <arm_group>
    <arm_group_label>Patient with T3-T4 ORL cancer, relevant to surgery and/or radiotherapy and/or chemotherapy.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient managed at the IUCT-O and by a private speech therapist (near the patient's home).</intervention_name>
    <description>Each patient included will have a video-assisted remote speech therapy consultation with a private speech therapist (near the patient's home) and the expert speech therapist of IUCT-O center.&#xD;
At the end of this video consultation, the patient and the private speech therapist will be asked to complete a satisfaction questionnaire.</description>
    <arm_group_label>Patient with T3-T4 ORL cancer, relevant to surgery and/or radiotherapy and/or chemotherapy.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years at study entry.&#xD;
&#xD;
          2. Patient with T3-T4 carcinological pathology of the VADS, relevant to surgery and/or&#xD;
             radiotherapy and/or chemotherapy.&#xD;
&#xD;
          3. Patient managed at the IUCT-O and by a private speech therapist (near the patient's&#xD;
             home).&#xD;
&#xD;
          4. Patient affiliated to a Social Security system in France.&#xD;
&#xD;
          5. Patient having signed informed consent prior to inclusion in the study and prior to&#xD;
             any specific study procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women.&#xD;
&#xD;
          2. Any psychological, familial, geographical or sociological condition that does not&#xD;
             allow for compliance with the medical follow-up and/or procedures foreseen in the&#xD;
             study protocol.&#xD;
&#xD;
          3. Patients deprived of their liberty or under legal protection (guardianship and&#xD;
             tutorship, safeguard of justice).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jérôme SARINI</last_name>
    <phone>05 31 15 60 16</phone>
    <email>sarini.jerome@iuct-oncopole.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Claude FARENC</last_name>
    <phone>05 31 15 51 97</phone>
    <email>farenc.jean-claude@iuct-oncopole.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme SARINI</last_name>
      <phone>05 31 15 60 16</phone>
      <email>sarini.jerome@iuct-oncopole.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jean-Claude FARENC</last_name>
      <phone>05 31 15 51 97</phone>
      <email>farenc.jean-claude@iuct-oncopole.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Video-Assisted Speech Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communication Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

